Lipid formulations of amphotericin B

Current Opinion in Infectious Diseases

Volumn 9, Issue 6, 1996, Pages 403-406

  Janknegt, Robert ^a   Van Etten, Els W M ^b   De Marie, Simon ^c  

^a Sittard Geleen Heerlen   (Netherlands)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; INTRALIPID; LIPID;

DRUG COST; DRUG EFFICACY; HUMAN; MYCOSIS; NEPHROTOXICITY; SHORT SURVEY;

EID: 0030473832     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-199612000-00008     Document Type: Short Survey

References (40)

1. Dupont B: Azole antifungal agents: emerging and inherent resistance. Curr Opin Infect Dis 1995, 8:424-427.
2. Van Etten EWM: Liposomal amphotericin B for invasive fungal infections. An experimental study in the leukopenic host [Thesis]. Rotterdam: University of Rotterdam; 1995.
3. Leenders ACAP, de Marie S: The use of lipid formulations of amphotericin B for systemic fungal infections. Leukemia. (In press). A review of clinical and animal experimental studies focussing on the presence or absence of an increased therapeutic index for lipid formulations. Increased efficacy was not invariably shown in all animal studies, sometimes only with extremely high dosages.
4. Tollemar J, Ringden O: Lipid formulations of amphotericin B. Less toxicity but at what economic cost? Drugs Safety 1995, 13:207-218.
5. Janknegt R, De Marie S, Bakker-Woudenberg IAJM, Crommelin DA: Liposomal and lipid formulations of amphotericin B, clinical pharmacokinetics. Clin Pharmacokinet 1992, 23:279-291.
6. De Marie S: Liposomal and lipid formulations of amphotericin B. Leukemia 1996, 10(suppl 2):S93-S96.
7. Hiemenz JW, Walsh TJ: Lipid formulations of amphotericin B: recent progress and future directions. Clin Infect Dis 1996, 22 (suppl 2):S133-S144.
8. Fromtling RA. Amphotericin B lipid complex. Drugs Fut 1995, 20:129-134.
9. Anaissie EJ, White MH, Ozun O, Singer C, Bodey GP et al: Abelcet (amphotericin B lipid complex) versus amphotericin B for treatment of invasive candidiasis: a prospective, randomized multicenter trial [Extended abstract]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, USA: American Society of Microbiology; 1995.
10. Sharkey PK, Graybill JR, Johnson ES, Hausrath SG, Poollard RB, Kolokathis A, Mildvan D, Fan-Havard P, Eng RHK, Patterson TF et al. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1996, 22:315-321.
11. Hiemenz JW, Lister J, Anaissie EJ, White HH, Dinubile M, Silber J, Horwith G, Lee LW: Emergency-use amphotericin B lipid complex (ABLC) in the treatment of patients with aspergillosis: historical-control comparison with amphotericin B [Abstract]. Blood 1995, 86 (suppl 1): 849.
12. Kline S, Larsen TA, Fieber L, Fishbach R, Greenwood M, Harris R, Kline MW, Tennican PO, Janoff EN: Limited toxicity of prolonged therapy with high doses of amphotericin B lipid complex. Clin Infect Dis 1995, 21:1154-1158.
13. Sufliarsky J, Sorkovska D, Kunova A, Helpianska L, Krcmery V: Breakthrough fungemia caused by Candida stellatoidea in a patient with lymphoma associated with shock, succesfully treated with amphotericin B lipid complex Infection 1995, 23:246-247.
14. Hay RJ: Amphotericin B lipid complex. Case History Series. J Drug Develop Clin Pract 1996, 4:1-12.
15. Sundar S, Murray HW: Cure of antimony-unresponsive indian visceral leishmaniasis with amphotericin B lipid complex. J Infect Dis 1996, 173:762-765.
16. Etten EWM van, Chander HR, Snijders SV, Bakker-Woudenberg IAJM: Interactions of liposomal amphotericin B with extracellular and intracellular Candida albicans. J Antimicrob Chemother 1995, 36:961-974.
17. Leenders ACAP, de Marie S, ten Cate MT, Bakker-Woudenberg IAJM, Verbrugh HA: Liposomal amphotericin B (AmBisome) reduces dissemination of infection as compared with amphotericin B desoxycholate (Fungizone) in a rat model of pulmonary aspergillosis. J Antimicrob Chemother 1996, 38:215-225.
18. Prentice HG, Catovsky D, Aoun M, Kvaloy S, Jacobs S, Herbrecht R, Schey SA, Bell AJ, Ellegaard J, Fiedler E, Fauser AA: AmBisome versus amphotericin B in patients with fever unresponsive to antibiotic therapy for 96 hours, or with confirmed fungal mycosis [Abstract]. 2nd International Symposium on Febrile Neutropenia, Brussels, 14-16 December 1995.
19. Hann IM, Stevens RF, Pinkerton CR, Dardyshire PJ, Gibson BES, Oakhill A, Eestermans GH: Safety and efficacy of two regimes of AmBisome versus amphotericin B as empiric antifungal treatment in neutropenic paediatric patients [Abstract]. 2nd International Symposium on Febrile Neutropenia, Brussels, 14-16 December 1995.
20. Leenders A, Reiss P, Portegies P, Clezy K, Borleffs J, Kauffman R, Hop W, de Marie S: A randomized trial of AmBisome 4mg/kg versus amphotericin B 0.7mg/kg for cryptococcal meningitis in HIV-infected patients [Abstract]. Program and Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy: New Orleans, USA, 1996.
21. Tollemar J, Höckerstedt K, Ericzon BG, Jalanko H, Ringdén O: Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients. Transplantation 1995, 59:45-50.
22. Ng TTC, Denning DW: Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections. Arch Intern Med 1995, 155:1093-1099.
23. Krueger W, Slockschlaeder M, Ruessmann B, Berger C, Hoffknecht M, Sobottka I, Kohlschuetter B, Kroschke G, Krueger N, Horstmann M et al. Experience with liposomal amphotericin B in 60 patients undergoing high-dose therapy and bone marrow or peripheral blood stem cell transplantation. Br J Haematol 1995, 91:684-690. This paper provides information on the clinical efficacy and safety of AmBisome in patients undergoing bone marrow or peripheral stem cell transplantation with suspected or documented fungal infections.
24. Coleman JM, Hogg GG, Rosenfeld JV, Waters KD: Invasive central nervous system aspergillosis: cure with liposomal amphotericin B, itraconazole, and radical surgery - case report and review of the literature. Neurosurgery 1995, 36:858-863.
25. Anonymous: An Aspergillus pneumonia case. Pharmacol Practice 1995, 312-313.
26. Purcell IF, Corris PA: Use of nebulised liposomal amphotericin B in the treatment of Aspergillus fumigatus pneumonia. Thorax 1995, 50:1321-1323.
27. Hosking MCK, MacDonald NE, Cornel G: Liposomal amphotericin B for postoperative Aspergillus fumigatus endocarditis. Ann Thorac Surg 1995, 59:1015-1017.
28. Baraia J, Munoz P, Bernaldo de Quiros JCL, Bouza E: Cutaneous mucormyosis in a heart transplant patient associated with a peripheral catheter. Eur J Clin Microbiol Infect Dis 1995, 14:813-815.
29. Gebhard F, Chastagner P, Maillot D, Kures L, Georges JL, Schmitt C: Evolution favorable d'une mucormycose orbitonasosinusienne compliqant le traitement d'induction d'une leucemie aigue lymphoblastique. Arch Pediatr 1995, 2:42-51.
30. Gangneux JP, Sulahian A, Garin YJ, Farinotti R, Derouin F: Therapy of visceral leishmaniasis due to Leishmanii infantum: experimental assessment of efficacy of AmBisome. Antimicrob Agents Chemother 1996, 40:1214-1218.
31. Oliva G, Gradoni L, Caramella P, de Luna R, Cortese L, Orsini S, Davidson RN, Persechino A: Activity of liposomal amphotericin B in dogs naturally infected with Leishmania infantum. J Antimicrob Chemother 1995, 36:1013-1019.
32. Gradoni L, Bruceson A, Desjeux P: Treatment of Mediterranean visceral leishmaniasis. WHO Bull CMS 1995, 73:191-197.
33. Amantea MA, Bowden RA, Forrest A, Working PK, Newman MS, Mamelok RD: Population pharmacokinetics and renal function sparing effects of amphotericin B colloidal dispersion in patients receiving bone marrow transplantation. Antimicrob Agents Chemother 1995, 39:2042-2047. This study is the first large-scale well designed pharmacokinetic study of any lipid formulation of amphotericin B in patients.
34. Oppenheim BA, Herbrecht R, Kusne S: The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses. Clin Infect Dis 1995, 21:1145-1153.
35. Bowden RA, Gays M, Gooley T, Mamelok RD, van Burk JA: Phase I study of amphotericin B colloidal dispersion for the treatment of invasive fungal infections after marrow transplant. J Infect Dis 1996, 173:1208-1215.
36. Valero G, Graybill JR: Successful treatment of cryptococcal meningitis with amphotericin B colloidal dispersion: report of four cases. Antimicrob Agents Chemother 1995, 39:2588-2590.
37. Anaissie E, Garwith M: Safety and efficacy of amphotericin B colloidal dispersion. Can J Infect Dis 1995, 6 (suppl C):Abs 632.
38. Trissel LA: Amphotericin B does not mix with fat emulsion [Letter]. Am J Health Syst Pharmacol 1995, 52:1463-1464.
39. Anonymous: Few pharmacoeconomic data to support use of lipid formulations of amphotericin B. Drugs Ther Perspect 1996, 7:14-16.
40. Etten EWM van, Kate MT ten, Stearne-Cullen LET, Bakker-Woudenberg IAJM: Amphotericin B liposomes with prolonged circulation in blood: in-vitro antifungal acitivity, toxicity and efficacy in systemic candidiasis in leukopenic mice. Antimicrob Agents Chemother 1995, 39:1954-1958.